List of Excipients in Branded Drug NAPROXEN SODIUM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
WALGREEN COMPANY	NAPROXEN SODIUM	naproxen sodium	0363-0102	FD&C BLUE NO. 1
WALGREEN COMPANY	NAPROXEN SODIUM	naproxen sodium	0363-0102	GELATIN
WALGREEN COMPANY	NAPROXEN SODIUM	naproxen sodium	0363-0102	GLYCERIN
WALGREEN COMPANY	NAPROXEN SODIUM	naproxen sodium	0363-0102	LACTIC ACID

Generic Drugs Containing NAPROXEN SODIUM

Company	Ingredient	NDC	Excipient
Walgreens	naproxen sodium	0363-0748	ALCOHOL
Walgreens	naproxen sodium	0363-0748	FD&C BLUE NO. 1
Walgreens	naproxen sodium	0363-0748	GELATIN
Walgreens	naproxen sodium	0363-0748	GLYCERIN

What are the Most Frequently-Used Excipients in NAPROXEN SODIUM?

# Of NDCs	Excipient
19	ALCOHOL
4	ALUMINUM OXIDE
7	BUTYL ALCOHOL
1	CARBOXYMETHYLCELLULOSE

Naproxen Sodium Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: August 13, 2026

Naproxen sodium is an off-patent NSAID with a mature oral solid-dose market, broad OTC distribution, and limited active-ingredient patent leverage. Commercial differentiation depends on excipient-enabled performance: rapid dissolution, tablet robustness, taste masking, gastrointestinal tolerability, dose flexibility, and manufacturing efficiency. The strongest opportunities are immediate-release tablets, orally disintegrating or chewable formats, liquid suspensions, combination products, and differentiated delivery systems that improve convenience without creating unacceptable regulatory or clinical risk.

What is the pharmaceutical and regulatory profile of naproxen sodium?

Naproxen sodium is the sodium salt of naproxen, a propionic-acid NSAID. It is used for temporary relief of minor aches and pains in OTC products and for prescription treatment of arthritis, dysmenorrhea, acute pain, and related inflammatory conditions.

Attribute	Naproxen sodium profile
Active ingredient	Naproxen sodium
Pharmacologic class	Nonsteroidal anti-inflammatory drug
Common OTC strength	220 mg naproxen sodium
Naproxen equivalent	Approximately 200 mg naproxen per 220 mg naproxen sodium tablet
Common prescription strengths	275 mg and 550 mg
Common dosage forms	Immediate-release tablets, caplets, liquid suspension
Typical route	Oral
Regulatory status	FDA-approved prescription products and OTC products under the NSAID monograph
Major brands	Aleve, Anaprox and authorized or generic equivalents
Main safety issues	Gastrointestinal bleeding, ulceration, renal toxicity, cardiovascular risk and hypersensitivity

The sodium salt has greater aqueous solubility than the free acid and is used to support faster dissolution and earlier exposure. The salt does not remove the class-wide NSAID risks. OTC labeling limits duration and daily dosing, while prescription labeling provides broader indications and dosing regimens.[1,2]

The FDA OTC NSAID monograph permits naproxen sodium for temporary relief of minor aches and pains when products meet the specified active-ingredient, labeling and dosing requirements.[3]

What excipients are used in naproxen sodium tablets?

Immediate-release naproxen sodium tablets typically use excipients for flow, compression, disintegration, lubrication, film coating and stability. The exact composition varies by manufacturer and strength.

Core excipient functions

Formulation function	Common excipient classes	Commercial purpose
Dilution and compressibility	Microcrystalline cellulose, lactose, starch, dibasic calcium phosphate	Controls tablet size and compression behavior
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Accelerates tablet breakup and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Film former	Hypromellose, polyvinyl alcohol	Protects the tablet and improves appearance
Plasticizer	Polyethylene glycol, propylene glycol	Improves coating flexibility
Opacifier or colorant	Titanium dioxide, iron oxides, approved lakes	Provides identification and light protection
Wetting agent	Polysorbates, sodium lauryl sulfate	Improves wetting of hydrophobic particles
Suspension stabilizer	Xanthan gum, sodium carboxymethylcellulose, carbomer	Controls sedimentation and redispersibility
Sweetener and flavor	Sucralose, saccharin sodium, sorbitol, flavors	Supports pediatric or chewable formats

Naproxen sodium is comparatively soluble relative to naproxen, but formulation performance remains sensitive to particle size, compression force, lubricant concentration and disintegrant selection. Excessive lubrication can slow wetting and dissolution. High compression can improve mechanical strength while delaying tablet breakup.

How should an excipient platform be designed for naproxen sodium?

A practical strategy separates products into three performance tiers.

Tier 1: Cost-optimized immediate-release tablets

The lowest-risk platform uses direct compression or dry granulation with:

• Microcrystalline cellulose as the principal filler and compression aid.
• Croscarmellose sodium or crospovidone as the primary disintegrant.
• Colloidal silicon dioxide for flow.
• Magnesium stearate or sodium stearyl fumarate for lubrication.
• A conventional hypromellose film coat.

This approach supports high-throughput manufacturing and broad generic substitution. The main development variables are tablet hardness, friability, disintegration time, dissolution profile, blend uniformity and punch sticking.

For a 220 mg OTC tablet, tablet size is commercially important. Consumers generally prefer a small caplet, but reducing excipient mass can impair manufacturability and handling. A high-functionality filler or co-processed excipient can reduce tablet weight while preserving tensile strength.

Tier 2: Fast-dissolving and convenience formats

Rapid-onset positioning requires control of both tablet disintegration and drug dissolution. Suitable approaches include:

• Crospovidone or croscarmellose sodium at optimized levels.
• Porous or spray-dried excipient systems.
• Wetting agents at low concentrations.
• Fine or engineered naproxen sodium particles.
• Orally disintegrating tablets using mannitol, crospovidone and taste-masking coatings.
• Chewable tablets using mannitol, sorbitol, flavor and high-intensity sweeteners.

The commercial challenge is taste. Naproxen sodium can produce a strong pharmaceutical taste, and sodium-containing formulations can create a saline aftertaste. Taste masking may require polymer coating, ion-exchange resin complexation, flavor systems or multiparticulate encapsulation.

An orally disintegrating product must balance rapid dispersion with acceptable mouthfeel. Excessive polymer coating can delay drug release and weaken the immediate-release claim. The product also needs packaging that limits moisture uptake and preserves tablet integrity.

Tier 3: Liquid and pediatric-oriented formulations

Naproxen sodium suspension products can differentiate through dose flexibility and swallowing convenience. Excipients must maintain:

• Uniform dose delivery after shaking.
• Rapid redispersion.
• Chemical stability.
• Acceptable viscosity.
• Microbiological control.
• Palatable flavor and low aftertaste.

A suspension may use xanthan gum or sodium carboxymethylcellulose as a rheology modifier, polysorbate 80 as a wetting agent, citrate or phosphate buffers for pH control, and an approved preservative system. Sodium benzoate or potassium sorbate may be considered where compatible with pH and labeling requirements.

Pediatric positioning requires more than a liquid format. The developer must address age-appropriate dosing, excipient exposure, palatability, accidental overdose risk and age-specific labeling. FDA inactive-ingredient databases and pediatric excipient guidance are relevant to product selection.[4,5]

What formulation patents protect naproxen sodium products?

The original composition-of-matter and basic product protections for naproxen and naproxen sodium have expired. The current competitive barrier is therefore formulation execution rather than the active ingredient.

Potentially protectable subject matter includes:

• Specific immediate-release tablet compositions.
• Narrow excipient ratios that produce defined dissolution behavior.
• Taste-masked particles or coated granules.
• Orally disintegrating tablets.
• Liquid suspension systems with defined redispersibility and stability.
• Fixed-dose combinations with gastroprotective agents.
• Modified-release or pulsatile-release systems.
• Manufacturing processes that improve content uniformity or reduce degradation.
• Packaging systems that control moisture or oxygen exposure.

A patent directed only to routine use of conventional excipients is likely to face validity and obviousness pressure. Stronger claims typically require a defined composition linked to an unexpected technical result, such as faster dissolution at high compression, improved stability under accelerated conditions, or sustained taste masking without delaying release.

What is the Orange Book status of naproxen sodium?

The Orange Book lists approved prescription drug products and related patent and exclusivity information. OTC monograph products such as many Aleve products are not protected through the same NDA patent-listing structure used for prescription products.[6]

Legacy prescription naproxen and naproxen sodium products have long-standing generic competition. Product-specific Orange Book entries should be reviewed by NDA, dosage form and strength because listings can differ across prescription products. A company seeking approval of a generic prescription product may need to address any currently listed patents through certification under the ANDA framework.

When does naproxen sodium lose exclusivity?

Naproxen sodium has already lost primary market exclusivity. Generic manufacturers have marketed prescription naproxen and naproxen sodium products for many years, and OTC competition is established.

Exclusivity category	Current commercial position
Active-ingredient patent	Expired
Original innovator exclusivity	Expired
OTC monograph protection	No conventional product-specific exclusivity
Generic entry	Established
Biosimilar exposure	Not applicable
Formulation patent risk	Product-specific and potentially relevant
Method-of-use patent risk	Generally limited for established indications, subject to live listings
Paragraph IV risk	Relevant only where a listed patent remains for a specific prescription product

There is no biosimilar pathway for naproxen sodium because it is a chemically synthesized small molecule, not a biologic. Competitive filings proceed through abbreviated or conventional small-molecule pathways rather than the 351(k) biosimilar process.

Which companies compete in naproxen sodium?

The market includes branded OTC manufacturers, generic pharmaceutical companies, contract manufacturers and private-label retailers.

Principal commercial groups

• Haleon, through Aleve and related naproxen sodium products.
• Teva, Viatris, Sun Pharmaceutical, Dr. Reddy's Laboratories and other generic manufacturers.
• Perrigo and private-label suppliers serving retailers.
• Contract development and manufacturing organizations supplying tablets, coatings and liquids.
• Excipient suppliers such as BASF, Roquette, Lubrizol, Evonik, Dow and Kerry.

Brand competition is concentrated in consumer recognition, price, package count, dosing convenience and retail placement. Generic competition is more sensitive to cost of goods, manufacturing yield, supply reliability and regulatory substitutability.

What commercial opportunities exist for naproxen sodium excipients?

The highest-value opportunities are tied to measurable product benefits rather than simply replacing one standard excipient with another.

Fast-dissolving OTC products

A rapid-dissolution platform can support consumer claims related to tablet breakup or ease of use, subject to applicable FDA labeling standards. Excipient suppliers can commercialize co-processed fillers, engineered disintegrants, porous carriers and low-moisture formulations.

Small, high-strength tablets

High-load formulations can reduce pill burden and packaging volume. The development challenge is maintaining tensile strength, low friability and rapid disintegration with limited excipient space.

Chewable and orally disintegrating products

These formats address consumers who have difficulty swallowing conventional caplets. The main technical barriers are taste masking, mouthfeel, tablet robustness and moisture sensitivity.

Pediatric and geriatric liquids

A stable, palatable suspension can support dosing flexibility and institutional use. Commercial value depends on dose accuracy, preservative strategy, bottle compatibility and redispersibility after storage.

Combination products

Potential combinations include naproxen sodium with:

• Proton-pump inhibitors or other gastroprotective agents.
• Acetaminophen for broader analgesic positioning.
• Caffeine for headache products.
• Antacids or buffering agents.

Combination products require careful clinical, regulatory and patent analysis. A gastroprotective combination may command a higher price but introduces additional active ingredients, drug-interaction issues, manufacturing complexity and possible new-drug approval requirements.

Packaging and stability systems

Moisture-barrier blister packs, desiccant bottles and unit-dose packaging can improve shelf life and dose control. These systems can create protectable product-by-process or packaging claims when linked to a demonstrated stability benefit.

What manufacturing and intellectual-property barriers affect naproxen sodium?

Manufacturing barriers are moderate rather than fundamental. Naproxen sodium is a well-established API, but scale-up can produce several recurring issues:

• Poor flow and segregation in high-dose blends.
• Punch sticking and picking during compression.
• Dissolution changes caused by lubricant overmixing.
• Coating defects on dense caplets.
• Moisture-related degradation or tablet softening.
• Suspension sedimentation and caking.
• Taste-masking polymers that delay drug release.
• API particle-size variation affecting dissolution.
• Cleaning validation concerns in shared facilities.

The strongest IP strategy combines formulation claims with process parameters and analytical performance. A formulation patent supported only by standard excipients and predictable outcomes is weaker than a patent tied to a reproducible manufacturing window and an unexpected dissolution or stability result.

What patent litigation and Paragraph IV risks affect naproxen sodium?

Naproxen sodium does not have the litigation profile of recently launched specialty drugs. Most commercial risk comes from product-specific disputes involving:

• A newly developed combination product.
• A novel modified-release dosage form.
• A branded prescription product with listed formulation patents.
• A method-of-use patent covering a narrow indication.
• Trade dress, trademark or consumer-labeling disputes in the OTC market.

Paragraph IV challenges remain possible for any prescription NDA product with a listed patent. The relevant assessment must be made at the specific NDA and patent-listing level. A generic applicant should also evaluate non-patent regulatory exclusivity, product-specific labeling restrictions and the scope of any carve-out.

How does naproxen sodium compare with competing NSAID products?

Product	Relative differentiation	Excipient opportunity	Competitive constraint
Naproxen sodium	Longer duration than some OTC analgesics; sodium salt supports dissolution	Fast-dissolve, small tablet, suspension and combination products	Established generic and OTC competition
Ibuprofen	High consumer familiarity and broad product range	Softgels, liquids, chewables and rapid-release systems	Strong brand and private-label competition
Aspirin	Low cost and broad historical use	Buffered, enteric-coated and chewable products	GI and bleeding concerns
Diclofenac	Strong prescription positioning	Enteric-coated, delayed-release and topical systems	More concentrated prescription market
Celecoxib	COX-2 selective prescription profile	Capsule, suspension and combination strategies	Prescription and safety-positioning constraints

Naproxen sodium’s commercial advantage is duration of action. Its disadvantage is the same NSAID class risk that affects competing products, including gastrointestinal and cardiovascular warnings. Excipient innovation cannot compensate for an unfavorable clinical or labeling profile.

What FDA milestones and regulatory standards apply?

Key regulatory considerations include:

1. Compliance with the FDA OTC NSAID monograph for eligible nonprescription products.[3]
2. ANDA requirements for generic prescription products.
3. Inactive-ingredient precedent and route-specific safety review.
4. Dissolution and bioequivalence testing.
5. Stability testing under ICH conditions.
6. Container-closure compatibility.
7. Microbiological quality for liquid products.
8. Accurate NSAID warnings and dosing instructions.
9. cGMP compliance under 21 C.F.R. Parts 210 and 211.
10. Nitrosamine and elemental-impurity risk assessment where applicable.[7,8]

Excipients should be selected from established compendial grades where possible. Novel excipient use can increase review time and toxicology requirements, particularly for chronic-use or pediatric products.

How strong is the naproxen sodium patent estate?

The active-ingredient patent estate is weak because the foundational protections are expired. Product-level formulation protection can still be commercially useful, but it is usually narrow and vulnerable to design-around.

Estate component	Strength
Naproxen sodium composition of matter	Low, expired
Basic oral tablet claims	Low to moderate
Novel excipient architecture	Moderate if supported by unexpected results
Taste masking	Moderate, depending on claims and prior art
Suspension technology	Moderate for specific systems
Combination products	Moderate to high if clinically and technically differentiated
Manufacturing process	Moderate where parameters are necessary and non-obvious
Biosimilar barriers	Not applicable
Geographic coverage	Dependent on country-specific filings and national-phase status

A commercially useful patent portfolio should protect the formulation, manufacturing method, particle engineering and product presentation separately. Filing only a broad composition claim leaves significant design-around exposure.

What generic launch scenarios exist?

Three launch scenarios are commercially realistic.

Low-cost commodity launch

A manufacturer uses standard excipients and competes on price, supply reliability and retailer access. This model has the lowest development risk but the thinnest margins.

Differentiated OTC launch

A company develops a smaller caplet, fast-dissolving tablet, chewable or liquid. The product can command a premium if the consumer benefit is clear and supported by compliant labeling.

Prescription or combination launch

A developer combines naproxen sodium with a gastroprotective or complementary analgesic component. This model can create new intellectual property but has higher clinical, regulatory and manufacturing costs.

What revenue exposure does naproxen sodium create?

Revenue exposure is concentrated in high-volume OTC analgesic channels. The market is mature, so sales growth is more likely to come from:

• Private-label conversion.
• Premium dosage forms.
• Retailer-exclusive packages.
• Smaller tablets and easier-swallow products.
• Liquid and pediatric formats.
• Combination products.
• Geographic expansion.
• Contract manufacturing and excipient supply agreements.

For incumbent brands, excipient changes carry a significant supply-chain risk. A reformulation can alter dissolution, stability, appearance, tablet dimensions or consumer acceptance. A change should be managed as a controlled product-development program rather than a simple raw-material substitution.

Key Takeaways

• Naproxen sodium is an established, off-patent NSAID with generic and OTC competition.
• The sodium salt supports oral dissolution, but excipient selection still controls tablet breakup, manufacturability and stability.
• The strongest excipient opportunities are fast-dissolving tablets, chewables, orally disintegrating tablets, liquids and combination products.
• Standard excipient substitutions have limited patent value unless linked to unexpected performance.
• Taste masking, suspension stability and moisture control are the main formulation barriers.
• Biosimilar risk does not apply because naproxen sodium is a small-molecule drug.
• Paragraph IV risk is product-specific and depends on any live Orange Book-listed patents for the relevant prescription NDA.
• The best IP strategy combines formulation, manufacturing, particle-engineering and packaging claims.
• Commercial returns are more likely from differentiated delivery and private-label scale than from active-ingredient exclusivity.

FAQs About Naproxen Sodium Excipient Strategy

Can naproxen sodium be formulated as an orally disintegrating tablet?

Yes. The formulation must control taste, mouthfeel, moisture sensitivity, mechanical strength and rapid drug release. Mannitol, crospovidone, flavor systems and taste-masking coatings are common development tools.

Which disintegrant is most suitable for naproxen sodium tablets?

Crospovidone and croscarmellose sodium are leading candidates. The optimal choice depends on compression force, particle size, lubricant exposure, target disintegration time and dissolution requirements.

Is a naproxen sodium suspension commercially attractive?

Yes. A suspension can provide dose flexibility and swallowing convenience, but commercial success depends on palatability, redispersibility, preservative performance and accurate dosing.

Can excipients reduce naproxen sodium gastrointestinal toxicity?

Excipients can alter dissolution, local exposure and administration convenience, but they do not eliminate the systemic gastrointestinal, renal or cardiovascular risks associated with NSAIDs. Gastroprotective combinations require separate clinical and regulatory evaluation.

Are naproxen sodium formulation patents likely to block generic entry?

They can block or delay a specific product if valid, enforceable and listed for the relevant prescription NDA. In practice, generic manufacturers can often design around narrow formulation claims, particularly where the claims rely on conventional excipients.

References

1. U.S. Food and Drug Administration. (2023). Aleve (naproxen sodium) tablet labeling. DailyMed.
2. U.S. Food and Drug Administration. (2023). Anaprox DS (naproxen sodium) prescribing information. DailyMed.
3. U.S. Food and Drug Administration. (2024). 21 C.F.R. § 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
5. U.S. Food and Drug Administration. (2014). General clinical pharmacology considerations for pediatric studies for drugs and biological products.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
7. International Council for Harmonisation. (2022). Q3C(R8): Impurities: Guideline for residual solvents.
8. International Council for Harmonisation. (2019). Q3D(R2): Guideline for elemental impurities.